Venkatraman Radhakrishnan/stjude.org
Oct 13, 2023, 17:15
Venkatraman Radhakrishnan: Inotuzumab take home points at SIOP 2023.
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute, shared on X/Twitter:
“Inotuzumab take home points at SIOP 2023:
- It is a bridge to transplant and Chimeric Antigen Receptor (CAR)-T cell therapy.
- Not effective in CNS.
- Risk of SOS.
- Can cause B cell aplasia so CAR-T might not work.
- CD22 negative cells can expand and relapse after intozumab.
- Inotuzumab before CAR-T doesn’t interfere with CAR-T.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 18:35
Dec 21, 2024, 18:33
Dec 21, 2024, 18:22
Dec 21, 2024, 18:14
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46